Tariq Khalil, MD
Internal Medicine · Mesa, AZNPI 1750337457
Payments from drug & device makers
Across 115 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$295
- Abbott$211
- Lilly USA, LLC$172
- Sanofi-aventis U.S. LLC$170
- GSK$132
- Novartis$119
- plus $971 from 21 others
What the payments were for
- Food & beverage$2,070100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $295 |
| Abbott | 12 | $211 |
| Lilly USA, LLC | 10 | $172 |
| Sanofi-aventis U.S. LLC | 14 | $170 |
| GSK | 7 | $132 |
| Novartis | 5 | $119 |
| Insulet Corporation | 5 | $119 |
| Novo Nordisk | 7 | $115 |
| Boehringer Ingelheim | 4 | $84 |
| Xeris Pharmaceuticals, Inc. | 4 | $81 |
| Dexcom, Inc. | 2 | $65 |
| Amgen | 3 | $57 |
| AbbVie | 3 | $54 |
| Philips North America LLC | 3 | $52 |
| Exact Sciences | 3 | $51 |
| Kowa Pharmaceuticals America, Inc. | 2 | $44 |
| Bayer | 2 | $39 |
| Angiodynamics, Inc. | 1 | $33 |
| Mylan Specialty L.p. | 2 | $33 |
| Saluda Medical Americas, Inc. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Bardy Diagnostics, Inc. | 1 | $17 |
| Impulse Dynamics (USA) Inc. | 1 | $17 |
| Merck | 1 | $15 |
| Cequr Corporation | 1 | $6 |
How this compares
$2,070 in reported general payments places this provider in the 85th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $157,164 |
| EliquisApixaban | 175 | $152,075 |
| JardianceEmpagliflozin | 125 | $144,504 |
| TrulicityDulaglutide | 80 | $85,253 |
| JanuviaSitagliptin Phosphate | 49 | $56,532 |
| MounjaroTirzepatide | 53 | $55,165 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 36 | $44,909 |
| FarxigaDapagliflozin Propanediol | 36 | $40,469 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $27,453 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $25,174 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 125 | $20,298 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $17,357 |
| MyrbetriqMirabegron | 19 | $15,928 |
| XareltoRivaroxaban | 18 | $14,774 |
| Spiriva HandihalerTiotropium Bromide | 16 | $12,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $115 | $157,164136 claims |
| Boehringer IngelheimJardiance | $84 | $144,504125 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $172 | $140,418133 claims |
| MerckJanuvia | $15 | $56,53249 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $170 | $44,90936 claims |
| AstraZenecaFarxiga | $295 | $40,46936 claims |
| GSKTrelegy Ellipta | $132 | $25,17425 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $15,92819 claims |
| AbbVieSynthroid | $54 | $3,45846 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Mesa
- Yessica SachdevaMesa$13.7M
- Tami BruceMesa$976K
- Ali ImranMesa$240K
- Louise TaberPhoenix$8.5M
- Janelle WeyerChandler$5.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
- Justin MoserScottsdale$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.